Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance Biopharma Inc.

www.theravance.com

Latest From Theravance Biopharma Inc.

How Drug Effects Are Assessed In Renally Impaired Patients Could Be Headed For A Change

US FDA advisory committee finds merit in each of four industry-suggested alternative approaches to the current paradigm for assessing the impact of renal impairment on drug exposures; agency's own 2010 draft guidance does not reflect its current thinking on the design of dedicated pharmacokinetic studies.

 

Advisory Committees Clinical Trials

Landos Leverages Advanced Computing For Autoimmune Disease Drug Development

Emerging Company Profile: Start-up Landos is raising money through a Series B financing to fund Phase II development of its lead oral, gut-restricted compound and described its plans in a video interview at the Biotech Showcase in San Francisco in January. 

 

 

StartUps and SMEs Companies

Glenmark’s Lonhala Version Hits ‘Intriguing’ Indian Nebulizer Market

Glenmark’s nebulized, long-acting muscarinic antagonist for COPD has hit the Indian market. Delivered via a novel mesh nebulizer, it is seen as likely catering to a relatively small patient group.
Commercial Strategy

Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations

Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Theravance Biopharma Inc.
  • Senior Management
  • Rick E Winningham, CEO
    Andrew Hindman, SVP, CFO
    Brett K Haumann, MD, SVP, Clin. Dev. & CMO
    Shehnaaz Suliman, MD, SVP, Corp. Dev. & Strategy
  • Contact Info
  • Theravance Biopharma Inc.
    Phone: (650) 808-6000
    901 Gateway Blvd.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register